| Product Code: ETC13372914 | Publication Date: Apr 2025 | Updated Date: Aug 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
| Market Size (2025) | USD 1.1 Billion |
| Forecast Size (2032) | USD 1.7 Billion |
| CAGR | 5.90% |
| Base Year | 2025 |
| Forecast Period | 2026-2032 |
| Largest Region | North America |
| Fastest Growing Region | Asia |
| Largest Segment | Parenteral Nutrition |
| Fastest Growing Segment | Pharmacological |
| Leading Companies | AbbVie, Fresenius Kabi, Baxter International, B. Braun, Hormone Therapeutics |

The Global Short Bowel Syndrome Market was estimated at USD 1.1 Billion in 2025 and is projected to reach USD 1.7 Billion by 2032, growing at a CAGR of 5.90% from 2026 to 2032.
The Global Short Bowel Syndrome (SBS) market is undergoing a transformative phase, primarily influenced by a rising prevalence of the condition. SBS often stems from surgical interventions requiring a substantial part of the small intestine to be removed. This shift towards targeted treatment options, including parenteral and enteral nutrition, highlights a market driven by clinical innovation.
The landscape of SBS treatments is evolving, with an increasing focus on novel therapies aimed at improving patient outcomes. Industry leaders are channeling resources into research and development, particularly in biologics and surgical methods, indicating a robust pipeline for innovative solutions. These advancements are crucial for addressing unmet medical needs and establishing benchmarks in patient care.
This graph illustrates the annual growth rates of the Global Short Bowel Syndrome Market from 2022 to 2032, highlighting a steady upward trajectory and projected expansion over the forecast period.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate (%) | Major Drivers |
| 2022 | 6.91 | Biosensor technology development helps reduce input costs in short bowel syndrome treatment. |
| 2023 | 5.84 | Providers are investing heavily in clinical trial pipelines related to short bowel syndrome therapies. |
| 2024 | 5.62 | Emerging telehealth platforms are reshaping patient interactions in the short bowel syndrome sector. |
| 2025 | 7.59 | As sustainability initiatives advance, the short bowel syndrome healthcare ecosystem evolves positively. |
| 2026 | 5.86 | Innovations in drug delivery systems enhance therapeutic efficacy for short bowel syndrome patients. |
| 2027 | 5.18 | Across North America, supply chain dynamics improve access to short bowel syndrome treatments. |
| 2028 | 9.39 | Patients increasingly seek digital therapeutics, driven by favorable regulatory changes for short bowel syndrome. |
| 2029 | 4.69 | The reliance on wearable monitoring devices signals a shift in short bowel syndrome patient management. |
| 2030 | 6.97 | Expanding skilled labor in clinical settings enhances care quality for short bowel syndrome patients. |
| 2031 | 6.11 | A growing emphasis on regional healthcare collaborations enriches the short bowel syndrome market ecosystem. |
| 2032 | 6.8 | A shift toward personalized treatment plans significantly alters short bowel syndrome patient outcomes. |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary research methodology, combining internal industry data, secondary research, and primary validation, updated periodically to reflect current market conditions. As markets evolve rapidly, figures for certain industries may vary slightly and are intended as informed estimates rather than absolute figures. For the most current market sizing, we recommend validating figures with a 6Wresearch analyst.
Below are some of the specific key takeaways from the market, including:
The Global Short Bowel Syndrome Market faces notable challenges that can hinder growth. One major restraint is the high cost associated with advanced therapies, which can exceed $100,000 annually for certain patients, placing financial pressure on healthcare providers and patients alike. Limited awareness among healthcare professionals and the public exacerbates these issues, contributing to late diagnoses. For example, healthcare systems often lack the specific training needed to recognize the complexities of SBS, leading to prolonged treatment timelines and poorer patient outcomes.
The Global Short Bowel Syndrome Market is witnessing several impactful trends that reshape treatment dynamics. One critical trend is the integration of advanced technologies like telemedicine for the management of SBS patients, enhancing access and continuity of care. For instance, a 2023 study highlighted that telehealth interventions could reduce hospital readmission rates by as much as 25%. Another emerging direction involves biopharmaceutical innovations, particularly targeted therapies designed to stimulate intestinal adaptation. Companies like Kliegman Biopharma are exploring treatments that leverage recombinant human GLP-2, which is expected to enter clinical trials in late 2024, showing promise in enhancing the quality of life and nutritional status of SBS patients.
Several future revenue opportunities are distinct within the Global Short Bowel Syndrome Market. One notable area is personalized treatment approaches that align with individual patient profiles. For instance, Hormone Therapeutics is pioneering a precision therapy that tailors hormone replacement based on genetic biomarker analysis, potentially increasing treatment efficacy. Additionally, expansion into emerging markets presents a lucrative avenue, where the prevalence of SBS is largely underreported. Companies aiming to enter these markets could benefit immensely from developing low-cost yet effective treatments tailored to local needs.
Parenteral Nutrition leads the Global Short Bowel Syndrome Market with a ~62% share in 2025, driving its dominance due to established application in severe cases. Furthermore, the Pharmacological segment is expected to exhibit the fastest growth, with a CAGR of 8.3% from 2026 to 2032. This growth is propelled by increasing R&D investments in drug formulations aimed at improving recovery rates and reducing hospital stays, establishing a significant competitive advantage in the treatment landscape.
GLP-2 Analog is projected to command the largest share in the Global Short Bowel Syndrome Market, accounting for ~40% share as of 2025. On the other hand, the Growth Hormones segment is anticipated to experience the fastest growth with a CAGR of 9.5% from 2026 to 2032. This expected surge can be attributed to the compound's dual action of enhancing nutrient absorption and stimulating intestinal growth, resulting in increased interest among clinicians and researchers alike.
Malabsorption is the leading application within the Global Short Bowel Syndrome Market, holding a ~55% share in 2025. This dominance roots in the condition's direct impact on nutrient absorption capabilities. Conversely, Nutritional Deficiency is predicted to be the fastest-growing application, experiencing a CAGR of 7.8% from 2026 to 2032. This growth highlights the increasing emphasis on nutritional management in SBS patients, reflecting heightened awareness among healthcare providers.
Hospitals are poised to dominate the Global Short Bowel Syndrome Market, with a ~70% share in 2025, owing to the high complexity of care necessary for SBS patients. Meanwhile, homecare services are set to grow the fastest, exhibiting a CAGR of 10.2% from 2026 to 2032. This growth is driven by increased patient preference for at-home treatments and advancements in home monitoring technologies that support long-term care solutions.
North America is expected to hold the largest share in the Global Short Bowel Syndrome Market, with approximately ~48% share in 2025, driven by advanced healthcare infrastructure and higher disease awareness. Additionally, Asia is positioned as the fastest-growing region, projected to achieve a CAGR of 7.0% from 2026 to 2032, bolstered by healthcare improvements and rising investments in medical technologies.
The regulatory landscape for the Global Short Bowel Syndrome Market is increasingly supportive of innovative solutions aimed at enhancing patient care. Governments are implementing various initiatives that not only aim to improve treatment modalities but also to bolster financial support for patients and healthcare providers.
The Global Short Bowel Syndrome Market is anticipated to experience structural changes informed by advancements in personalized medicine and telehealth applications. As of 2023, AbbVie’s ongoing investment in gene therapies demonstrates a shift toward developing treatments that offer tailored solutions, potentially enhancing efficacy. Furthermore, the integration of digital health technologies in managing SBS patients is expected to reshape care delivery models, as healthcare providers increasingly leverage remote monitoring to improve patient outcomes while optimizing costs.
Several key developments have been reported in the Global Short Bowel Syndrome Market, reflecting ongoing innovation and commitment to enhancing patient care.
The competitive structure of the Global Short Bowel Syndrome Market is relatively fragmented. While major companies hold significant market shares, numerous smaller firms are increasingly emerging with specialized solutions, increasing competition. This dynamic encourages innovation among the leading players.
| Leading Company | Core Strength | Strategic Focus |
|---|---|---|
| AbbVie | Strong R&D capabilities with significant investments in novel therapies. | Focus on biologics and gene therapies for tailored patient solutions. |
| Fresenius Kabi | Expertise in enteral and parenteral nutrition solutions. | Expansion of product offerings in nutrition to meet varied patient needs. |
| B. Braun | Established global presence with advanced manufacturing capabilities. | Partnerships to innovate therapies and enhance treatment efficacy. |
| Baxter International | Diverse therapy portfolio with a focus on chronic conditions. | Investment in digital health solutions for streamlined patient management. |
| Hormone Therapeutics | Pioneering personalized medicine approaches for hormone-related therapies. | Emphasis on genetic profiling to enhance treatment target precision. |
As the Global Short Bowel Syndrome Market evolves, fostered by technological advancements and personalized care strategies, leading companies are likely to enhance their competitive positioning through continual innovation.
Global Short Bowel Syndrome Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Short Bowel Syndrome Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Short Bowel Syndrome Market Revenues & Volume, 2022 & 2032F |
3.3 Global Short Bowel Syndrome Market - Industry Life Cycle |
3.4 Global Short Bowel Syndrome Market - Porter's Five Forces |
3.5 Global Short Bowel Syndrome Market Revenues & Volume Share, By Regions, 2022 & 2032F |
3.6 Global Short Bowel Syndrome Market Revenues & Volume Share, By Treatment Type, 2022 & 2032F |
3.7 Global Short Bowel Syndrome Market Revenues & Volume Share, By Drug Type, 2022 & 2032F |
3.8 Global Short Bowel Syndrome Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.9 Global Short Bowel Syndrome Market Revenues & Volume Share, By End Use, 2022 & 2032F |
4 Global Short Bowel Syndrome Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Short Bowel Syndrome Market Trends |
6 Global Short Bowel Syndrome Market, 2022-2032 |
6.1 Global Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
6.1.1 Overview & Analysis |
6.1.2 Global Short Bowel Syndrome Market, Revenues & Volume, By Parenteral Nutrition, 2022-2032 |
6.1.3 Global Short Bowel Syndrome Market, Revenues & Volume, By Enteral Nutrition, 2022-2032 |
6.1.4 Global Short Bowel Syndrome Market, Revenues & Volume, By Pharmacological, 2022-2032 |
6.1.5 Global Short Bowel Syndrome Market, Revenues & Volume, By Surgical, 2022-2032 |
6.1.6 Global Short Bowel Syndrome Market, Revenues & Volume, By Others, 2022-2032 |
6.2 Global Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
6.2.1 Overview & Analysis |
6.2.2 Global Short Bowel Syndrome Market, Revenues & Volume, By GLP-2 Analog, 2022-2032 |
6.2.3 Global Short Bowel Syndrome Market, Revenues & Volume, By Growth Hormones, 2022-2032 |
6.2.4 Global Short Bowel Syndrome Market, Revenues & Volume, By Anti-Diarrheal, 2022-2032 |
6.2.5 Global Short Bowel Syndrome Market, Revenues & Volume, By Immunosuppressants, 2022-2032 |
6.3 Global Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
6.3.1 Overview & Analysis |
6.3.2 Global Short Bowel Syndrome Market, Revenues & Volume, By Malabsorption, 2022-2032 |
6.3.3 Global Short Bowel Syndrome Market, Revenues & Volume, By Intestinal Failure, 2022-2032 |
6.3.4 Global Short Bowel Syndrome Market, Revenues & Volume, By Nutritional Deficiency, 2022-2032 |
6.3.5 Global Short Bowel Syndrome Market, Revenues & Volume, By Chronic Conditions, 2022-2032 |
6.4 Global Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
6.4.1 Overview & Analysis |
6.4.2 Global Short Bowel Syndrome Market, Revenues & Volume, By Hospitals, 2022-2032 |
6.4.3 Global Short Bowel Syndrome Market, Revenues & Volume, By Clinics, 2022-2032 |
6.4.4 Global Short Bowel Syndrome Market, Revenues & Volume, By Homecare, 2022-2032 |
6.4.5 Global Short Bowel Syndrome Market, Revenues & Volume, By Specialty Centers, 2022-2032 |
7 North America Short Bowel Syndrome Market, Overview & Analysis |
7.1 North America Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
7.2 North America Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
7.2.1 United States (US) Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
7.2.2 Canada Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
7.2.3 Rest of North America Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
7.3 North America Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
7.4 North America Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
7.5 North America Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
7.6 North America Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
8 Latin America (LATAM) Short Bowel Syndrome Market, Overview & Analysis |
8.1 Latin America (LATAM) Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
8.2 Latin America (LATAM) Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
8.2.1 Brazil Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
8.2.2 Mexico Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
8.2.3 Argentina Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
8.2.4 Rest of LATAM Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
8.3 Latin America (LATAM) Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
8.4 Latin America (LATAM) Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
8.5 Latin America (LATAM) Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
8.6 Latin America (LATAM) Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
9 Asia Short Bowel Syndrome Market, Overview & Analysis |
9.1 Asia Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
9.2 Asia Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
9.2.1 India Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
9.2.2 China Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
9.2.3 Japan Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
9.2.4 Rest of Asia Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
9.3 Asia Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
9.4 Asia Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
9.5 Asia Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
9.6 Asia Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
10 Africa Short Bowel Syndrome Market, Overview & Analysis |
10.1 Africa Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
10.2 Africa Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
10.2.1 South Africa Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
10.2.2 Egypt Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
10.2.3 Nigeria Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
10.2.4 Rest of Africa Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
10.3 Africa Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
10.4 Africa Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
10.5 Africa Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
10.6 Africa Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
11 Europe Short Bowel Syndrome Market, Overview & Analysis |
11.1 Europe Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
11.2 Europe Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
11.2.1 United Kingdom Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
11.2.2 Germany Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
11.2.3 France Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
11.2.4 Rest of Europe Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
11.3 Europe Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
11.4 Europe Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
11.5 Europe Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
11.6 Europe Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
12 Middle East Short Bowel Syndrome Market, Overview & Analysis |
12.1 Middle East Short Bowel Syndrome Market Revenues & Volume, 2022-2032 |
12.2 Middle East Short Bowel Syndrome Market, Revenues & Volume, By Countries, 2022-2032 |
12.2.1 Saudi Arabia Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
12.2.2 UAE Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
12.2.3 Turkey Short Bowel Syndrome Market, Revenues & Volume, 2022-2032 |
12.3 Middle East Short Bowel Syndrome Market, Revenues & Volume, By Treatment Type, 2022-2032 |
12.4 Middle East Short Bowel Syndrome Market, Revenues & Volume, By Drug Type, 2022-2032 |
12.5 Middle East Short Bowel Syndrome Market, Revenues & Volume, By Application, 2022-2032 |
12.6 Middle East Short Bowel Syndrome Market, Revenues & Volume, By End Use, 2022-2032 |
13 Global Short Bowel Syndrome Market Key Performance Indicators |
14 Global Short Bowel Syndrome Market - Export/Import By Countries Assessment |
15 Global Short Bowel Syndrome Market - Opportunity Assessment |
15.1 Global Short Bowel Syndrome Market Opportunity Assessment, By Countries, 2022 & 2032F |
15.2 Global Short Bowel Syndrome Market Opportunity Assessment, By Treatment Type, 2022 & 2032F |
15.3 Global Short Bowel Syndrome Market Opportunity Assessment, By Drug Type, 2022 & 2032F |
15.4 Global Short Bowel Syndrome Market Opportunity Assessment, By Application, 2022 & 2032F |
15.5 Global Short Bowel Syndrome Market Opportunity Assessment, By End Use, 2022 & 2032F |
16 Global Short Bowel Syndrome Market - Competitive Landscape |
16.1 Global Short Bowel Syndrome Market Revenue Share, By Companies, 2025 |
16.2 Global Short Bowel Syndrome Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here